Literature DB >> 25778535

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.

Mir Farshid Alemdehy1, Jurgen R Haanstra1, Hans W J de Looper1, Paulina M H van Strien1, Judith Verhagen-Oldenampsen1, Yvette Caljouw1, Mathijs A Sanders1, Remco Hoogenboezem1, Arnoud H de Ru2, George M C Janssen2, Stephanie E Smetsers3, Marc B Bierings4, Peter A van Veelen2, Marieke von Lindern1, Ivo P Touw1, Stefan J Erkeland1.   

Abstract

Interstrand crosslinks (ICLs) are toxic DNA lesions that cause severe genomic damage during replication, especially in Fanconi anemia pathway-deficient cells. This results in progressive bone marrow failure and predisposes to acute myeloid leukemia (AML). The molecular mechanisms responsible for these defects are largely unknown. Using Ercc1-deficient mice, we show that Trp53 is responsible for ICL-induced bone marrow failure and that loss of Trp53 is leukemogenic in this model. In addition, Ercc1-deficient myeloid progenitors gain elevated levels of miR-139-3p and miR-199a-3p with age. These microRNAs exert opposite effects on hematopoiesis. Ectopic expression of miR-139-3p strongly inhibited proliferation of myeloid progenitors, whereas inhibition of miR-139-3p activity restored defective proliferation of Ercc1-deficient progenitors. Conversely, the inhibition of miR-199a-3p functions aggravated the myeloid proliferation defect in the Ercc1-deficient model, whereas its enforced expression enhanced proliferation of progenitors. Importantly, miR-199a-3p caused AML in a pre-leukemic mouse model, supporting its role as an onco-microRNA. Target genes include HuR for miR-139-3p and Prdx6, Runx1, and Suz12 for miR-199a-3p. The latter genes have previously been implicated as tumor suppressors in de novo and secondary AML. These findings show that, in addition to TRP53-controlled mechanisms, miR-139-3p and miR-199a-3p are involved in the defective hematopoietic function of ICL-repair deficient myeloid progenitors.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25778535     DOI: 10.1182/blood-2014-11-612507

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice.

Authors:  M F Alemdehy; H W J de Looper; F G Kavelaars; M A Sanders; R Hoogenboezem; B Löwenberg; P J M Valk; I P Touw; S J Erkeland
Journal:  Leukemia       Date:  2016-06-04       Impact factor: 11.528

2.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

3.  MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.

Authors:  Abdel-Rahman N Zekri; Enas Reda El-Sisi; Amira Salah El-Din Youssef; Mahmoud M Kamel; Auhood Nassar; Ola Sayed Ahmed; Mohamed El Kassas; Ahmed Barakat Barakat; Alaa Ismail Abd El-Motaleb; Abeer A Bahnassy
Journal:  PLoS One       Date:  2018-03-13       Impact factor: 3.240

4.  MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis.

Authors:  Christine Roden; Jun Lu
Journal:  Curr Stem Cell Rep       Date:  2016-07-01

5.  miR-139 acts as a tumor suppressor in T-cell acute lymphoblastic leukemia by targeting CX chemokine receptor 4.

Authors:  Ling Qin; Hui-Yang Deng; Sheng-Jiang Chen; Wei Wei; Yi-Ting Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

6.  Diverse Evolutionary Trajectories for Small RNA Biogenesis Genes in the Oomycete Genus Phytophthora.

Authors:  Stephanie R Bollmann; Yufeng Fang; Caroline M Press; Brett M Tyler; Niklaus J Grünwald
Journal:  Front Plant Sci       Date:  2016-03-15       Impact factor: 5.753

7.  microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.

Authors:  Viviana Vallacchi; Chiara Camisaschi; Matteo Dugo; Elisabetta Vergani; Paola Deho; Ambra Gualeni; Veronica Huber; Annunziata Gloghini; Andrea Maurichi; Mario Santinami; Marialuisa Sensi; Chiara Castelli; Licia Rivoltini; Monica Rodolfo
Journal:  Genes (Basel)       Date:  2016-12-14       Impact factor: 4.096

8.  MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia.

Authors:  K Krowiorz; J Ruschmann; C Lai; M Ngom; T Maetzig; V Martins; A Scheffold; E Schneider; N Pochert; C Miller; L Palmqvist; A Staffas; M Mulaw; S R Bohl; C Buske; M Heuser; J Kraus; K O'Neill; C L Hansen; O I Petriv; H Kestler; H Döhner; L Bullinger; K Döhner; R K Humphries; A Rouhi; F Kuchenbauer
Journal:  Blood Cancer J       Date:  2016-12-09       Impact factor: 11.037

Review 9.  MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies.

Authors:  Stephanie Rebecca Setijono; Hyog Young Kwon; Su Jung Song
Journal:  Front Oncol       Date:  2018-01-30       Impact factor: 6.244

10.  miR‑199a‑3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2.

Authors:  Ying-Bo Li; Qun Wu; Jie Liu; Yong-Zhi Fan; Kai-Feng Yu; Yi Cai
Journal:  Mol Med Rep       Date:  2017-06-28       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.